Poolbeg Pharma PLC Annual Report & AGM Notice
May 09 2024 - 2:00AM
RNS Regulatory News
RNS Number : 6173N
Poolbeg Pharma PLC
09 May 2024
Poolbeg Pharma
plc
Annual Report & AGM
Notice
9 May
2024- Poolbeg
Pharma (AIM: POLB,
OTCQB: POLBF, 'Poolbeg' or the 'Company'), a
biopharmaceutical company focussed on the development and
commercialisation of innovative medicines targeting diseases with a
high unmet medical need, confirms that the
Company's Annual Report and Accounts for the period ended 31
December 2023 and the notice of Annual General Meeting ("AGM") will
be posted to shareholders today.
The 2023 Annual Report and Accounts,
the Notice of AGM and accompanying form of proxy are available to
download from the Company's website: https://www.poolbegpharma.com/
The Annual General Meeting will be
held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N
8AF, United Kingdom on 13 June 2024 at
2pm.
Enquiries
|
Poolbeg Pharma
Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO
|
+44 (0) 207 183 1499
|
|
Cavendish Capital Markets Ltd (Nominated
Adviser & Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM)
|
+44 (0) 207 220 0500
|
|
Shore Capital Stockbrokers
Ltd (Joint Broker)
David Coaten, Harry Davies-Ball
(Corporate Advisory), Malachy McEntyre, Isobel Jones
(Corporate Broking)
|
+44 (0) 207 408 4090
|
|
J&E
Davy (Joint Broker)
Anthony Farrell, Niall
Gilchrist
|
+353 (0) 1 679 6363
|
|
Optimum
Strategic Communications
Nick Bastin, Vici Rabbetts, Elena
Bates
|
+44 (0) 208 078 4357
poolbeg@optimumcomms.com
|
About Poolbeg Pharma
Poolbeg Pharma plc is committed to
the development and commercialisation of innovative medicines
targeting diseases with a high unmet medical need, with a growing
emphasis on rare and orphan diseases. Its model focusses upon
developing its exciting clinical assets and commercialising
approved and marketed drugs to support the
growth of the Company and the development
of its robust pipeline of innovative products, thereby driving
significant value creation.
Poolbeg is led by an experienced
leadership team with a history of delivering significant
shareholder value. The team has been strengthened by the
appointment of three former members of the Amryt Pharma plc
leadership team, with the intention of repeating Amryt's success
and generating near term revenues.
Poolbeg's clinical programmes target
large addressable markets including cancer immunotherapy-induced
CRS, infectious disease, and metabolic conditions such as obesity
with the development of an oral GLP-1R agonist. It uses a
cost-effective development philosophy to generate high quality
human data to support partnering and further development. Its
AI-led infectious disease programmes analyse unique data from human
challenge trials to identify clinically relevant drug targets and
treatments, leading to faster development and greater commercial
appeal.
For more information, please go
to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
ACSBVLFBZELFBBF
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Dec 2023 to Dec 2024
